Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Advent PharmaDHA:ADVENT -2.44%32 Debt-to-EBITDA is 0.00 as of . 20. GuruFocus rates DHA:ADVENT with a GF Score™ of 32/100. Among 683 Drug Manufacturers companies, Advent Pharma ranks worse than 146412.74% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Advent Pharma's Debt-to-EBITDA or its related term are showing as below:
DHA:ADVENT's Debt-to-EBITDA is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.63 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Advent Pharma Debt-to-EBITDA Related Terms
Advent Pharma Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Advent Pharma's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advent Pharma Debt-to-EBITDA Chart
Advent Pharma Annual Data
Trend
Debt-to-EBITDA
Advent Pharma Semi-Annual Data
Debt-to-EBITDA
DHA:ADVENT vs : Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Advent Pharma's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advent Pharma Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Advent Pharma's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Advent Pharma's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (. 20) EBITDA data.
Advent Pharma (DHA:ADVENT) has a Debt-to-EBITDA of 0.00 as of . 20. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Advent Pharma. According to the industry distribution chart, Advent Pharma ranks #999999 out of 683 companies in the Drug Manufacturers industry.
Is Advent Pharma's Debt-to-EBITDA too high?
Advent Pharma's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Advent Pharma ranks #999999 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Advent Pharma has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Advent Pharma's Debt-to-EBITDA compare to ?
According to the Drug Manufacturers industry distribution chart, Advent Pharma ranks #999999 out of 683 companies for Debt-to-EBITDA. This places Advent Pharma in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.63, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Advent Pharma. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advent Pharma's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advent Pharma stock overvalued right now?
Advent Pharma (DHA:ADVENT) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Advent Pharma's overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Advent Pharma (DHA:ADVENT), the current Debt-to-EBITDA is 0.00 as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ADVENT has been successfully added to your 
